Plerixafor use for peripheral blood stem cell mobilization in Korea

نویسندگان

  • Seok Jin Kim
  • Dok Hyun Yoon
  • Deok-Hwan Yang
  • Hyeon Seok Eom
  • Seok Goo Cho
  • Sung-Soo Yoon
  • Jae Hoon Lee
  • Won Seog Kim
  • Cheolwon Suh
چکیده

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Hematologic Malignancy Branch, National Cancer Center, Ilsan, Department of Internal Medicine, St. Mary Hospital, The Catholic University of Korea, Department of Internal Medicine, Seoul National University Hospiltal, Seoul, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Hematopoietic stem cell mobilization: current status and future perspective

Autologous stem cell transplantation (ASCT), high-dose chemotherapy followed by hematopoietic stem cell rescue, is a widely used therapeutic strategy especially for some patients with hematological malignancies such as malignant lymphoma or multiple myeloma (MM). Because successful ASCT is crucial in these patients for improving overall survival [1], collection of a sufficient number of hematop...

متن کامل

Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation

In allogeneic stem cell mobilization, peripheral blood stem cell mobilization with filgrastim can be considered standard of care. Poor mobilizers may be at risk for inadequate stem cell collection during apheresis. He we present a successful case of salvage plerixafor use with filgrastim in a haploidentical identical transplant patient.

متن کامل

Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.

Many institutions have adopted algorithms based on preapheresis circulating CD34+ cell counts to optimize the use of plerixafor. However, a circulating peripheral blood CD34+ cell threshold that predicts mobilization failure has not been defined. The superiority of plerixafor + granulocyte colony-stimulating factor (G-CSF) over placebo + G-CSF for hematopoietic stem cell mobilization and collec...

متن کامل

Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization

The combination of filgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood progenitor cell collection. In this ...

متن کامل

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran

High-dose chemotherapy and autologous stem cell transplantation (SCT) have become an effective care for many patients with hematological malignancies. Harvesting the stem cells is one the most important parts of SCT. The two most commonly used mobilization regimens are the use of granulocyte colony-stimulating factor (G-CSF) or G-CSF plus chemotherapy. However, about 10-30% of patients are unab...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 48  شماره 

صفحات  -

تاریخ انتشار 2013